Day One Biopharmaceuticals (DAWN) Competitors $8.07 -0.12 (-1.47%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.07 0.00 (0.00%) As of 03/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, and BHVNShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Alvotech Immunovant Viking Therapeutics Rhythm Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Merus Protagonist Therapeutics Apellis Pharmaceuticals Biohaven Day One Biopharmaceuticals (NASDAQ:DAWN) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Is DAWN or ALVO more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% Alvotech -123.47%N/A -35.87% Does the media refer more to DAWN or ALVO? In the previous week, Alvotech had 16 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 21 mentions for Alvotech and 5 mentions for Day One Biopharmaceuticals. Alvotech's average media sentiment score of 0.76 beat Day One Biopharmaceuticals' score of 0.44 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 3 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in DAWN or ALVO? Day One Biopharmaceuticals received 46 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 69.74% of users gave Day One Biopharmaceuticals an outperform vote while only 50.00% of users gave Alvotech an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes5369.74% Underperform Votes2330.26% AlvotechOutperform Votes750.00% Underperform Votes750.00% Do institutionals and insiders believe in DAWN or ALVO? 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Alvotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, DAWN or ALVO? Day One Biopharmaceuticals has a beta of -1.38, meaning that its stock price is 238% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Do analysts recommend DAWN or ALVO? Day One Biopharmaceuticals presently has a consensus target price of $32.29, suggesting a potential upside of 300.07%. Alvotech has a consensus target price of $18.00, suggesting a potential upside of 88.48%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, DAWN or ALVO? Day One Biopharmaceuticals has higher earnings, but lower revenue than Alvotech. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M6.24-$188.92M-$1.08-7.47Alvotech$391.87M7.35-$551.73M-$1.85-5.16 SummaryDay One Biopharmaceuticals beats Alvotech on 12 of the 19 factors compared between the two stocks. Remove Ads Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$817.94M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-7.837.1723.3318.67Price / Sales6.24220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book2.036.396.894.23Net Income-$188.92M$142.12M$3.20B$247.15M7 Day Performance-1.94%-5.06%-2.98%-2.17%1 Month Performance-10.93%-7.49%1.63%-5.68%1 Year Performance-51.15%-10.91%9.45%-0.74% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.925 of 5 stars$8.07-1.5%$32.29+300.1%-51.2%$817.94M$131.16M-7.8360Analyst ForecastALVOAlvotech2.0141 of 5 stars$11.31+0.1%$18.00+59.2%-21.8%$3.41B$391.87M-6.111,026Earnings ReportNews CoverageIMVTImmunovant2.4683 of 5 stars$20.02+2.6%$42.90+114.3%-43.1%$3.40BN/A-7.64120VKTXViking Therapeutics4.2297 of 5 stars$29.83-3.4%$97.67+227.4%-68.7%$3.35BN/A-29.8320Analyst ForecastRYTMRhythm Pharmaceuticals4.4107 of 5 stars$52.34+2.7%$69.31+32.4%+26.5%$3.31B$130.13M-12.09140Analyst RevisionSRRKScholar Rock4.0003 of 5 stars$34.72+0.3%$40.86+17.7%+84.9%$3.29B$33.19M-14.77140Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.3914 of 5 stars$35.20+2.1%$72.64+106.4%-25.8%$3.28B$1.04M-9.44210Analyst ForecastMRUSMerus2.1676 of 5 stars$47.22+0.3%$85.31+80.7%-0.9%$3.26B$36.13M-11.9537Analyst ForecastNews CoveragePTGXProtagonist Therapeutics3.6219 of 5 stars$53.01-3.2%$61.22+15.5%+69.0%$3.25B$434.43M19.93120Analyst ForecastPositive NewsAPLSApellis Pharmaceuticals4.4097 of 5 stars$25.11+1.8%$45.53+81.3%-58.7%$3.15B$781.37M-12.37770BHVNBiohaven3.8659 of 5 stars$29.73+2.0%$63.15+112.4%-49.6%$3.03BN/A-3.18239 Remove Ads Related Companies and Tools Related Companies Alvotech Competitors Immunovant Competitors Viking Therapeutics Competitors Rhythm Pharmaceuticals Competitors Scholar Rock Competitors Crinetics Pharmaceuticals Competitors Merus Competitors Protagonist Therapeutics Competitors Apellis Pharmaceuticals Competitors Biohaven Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
